Gracell Biotechnologies to Report Fourth Quarter and Fiscal 2020 Financial Results on Tuesday, March 9, 2021

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) announced it will release its financial results for Q4 and fiscal year 2020 on March 9, 2021, after U.S. market close. The management will hold a conference call on March 10, 2021, at 8:00 a.m. ET to discuss these results and recent business developments. Investors can access a replay of the webcast on Gracell's investor relations website for 90 days. The company focuses on developing innovative cell therapies through its FasTCAR and TruUCAR platforms, addressing challenges in the CAR-T therapy industry.

Positive

• Upcoming release of Q4 and fiscal year 2020 financial results may provide insights into company performance.
• Management's conference call scheduled for March 10, 2021, to discuss financial results and business developments.

Negative

• None.

SUZHOU and SHANGHAI, China, Feb. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it plans to release financial results for the fourth quarter and year ended December 31, 2020 after the close of the U.S. financial markets on Tuesday, March 9. Gracell's management team plans to host a corresponding conference call beginning at 8:00 a.m. Eastern Time on Wednesday, March 10, to discuss the financial results and recent business developments. A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

Conference call and webcast details:
Wednesday, March 10, 2021 @ 8:00am ET
Investor domestic dial-in: 877-407-0784
Investor international dial-in: +1 201-689-8560
Conference ID: 13716516
Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.

Media contact

Linc He
Linc.he@gracellbio.com
+86 021 64031522

Investor contact
Gracie Tong
Gracie.tong@gracellbio.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/gracell-biotechnologies-to-report-fourth-quarter-and-fiscal-2020-financial-results-on-tuesday-march-9-2021-301232997.html

SOURCE Gracell Biotechnologies

FAQ

When will Gracell Biotechnologies report its Q4 and fiscal 2020 financial results?

Gracell Biotechnologies will report its Q4 and fiscal 2020 financial results on March 9, 2021.

What is the date and time for Gracell's conference call?

The conference call is scheduled for March 10, 2021, at 8:00 a.m. ET.

How can I access the webcast of Gracell's conference call?

The webcast can be accessed through Gracell's investor relations website shortly after the call.

What is the focus of Gracell Biotechnologies?

Gracell focuses on discovering and developing highly efficacious and affordable cell therapies.